Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers
Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, Price RW. Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers. Journal Of Neuroimmune Pharmacology 2006, 2: 112-119. PMID: 18040834, DOI: 10.1007/s11481-006-9035-1.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-HIV AgentsBiomarkersCombinatorial Chemistry TechniquesDrug Delivery SystemsHIV InfectionsHumansNeurodegenerative DiseasesConceptsCNS HIV infectionAIDS dementia complexHIV infectionBrain injuryTreatment targetsCentral nervous system infectionNeurodegenerative diseasesSystemic HIV infectionComorbidities of patientsNervous system infectionAdjuvant treatment approachesCerebrospinal fluid markersRational trial designIntrathecal immunoactivationSystem infectionDementia complexAvailable treatmentsClinical trialsFluid markersTrial designTreatment approachesClinical practiceExperimental therapeuticsPatientsInfection